CN112074269A - 用于男性避孕的非激素组合物和方法 - Google Patents

用于男性避孕的非激素组合物和方法 Download PDF

Info

Publication number
CN112074269A
CN112074269A CN201980030077.4A CN201980030077A CN112074269A CN 112074269 A CN112074269 A CN 112074269A CN 201980030077 A CN201980030077 A CN 201980030077A CN 112074269 A CN112074269 A CN 112074269A
Authority
CN
China
Prior art keywords
composition
alpha
silodosin
daily
contraceptive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980030077.4A
Other languages
English (en)
Chinese (zh)
Inventor
纪尧姆·埃尔格拉维
迈赫迪·埃尔格拉维
P·佩林
S·德鲁彼
V·阿加顿-梅里奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metso Lab
Original Assignee
Metso Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metso Lab filed Critical Metso Lab
Publication of CN112074269A publication Critical patent/CN112074269A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN201980030077.4A 2018-03-23 2019-03-22 用于男性避孕的非激素组合物和方法 Pending CN112074269A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862763129P 2018-03-23 2018-03-23
EP18305328 2018-03-23
EP18305328.9 2018-03-23
US62/763129 2018-03-23
PCT/EP2019/057267 WO2019180217A1 (en) 2018-03-23 2019-03-22 Non-hormonal compositions and methods for male contraception

Publications (1)

Publication Number Publication Date
CN112074269A true CN112074269A (zh) 2020-12-11

Family

ID=65955198

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980030077.4A Pending CN112074269A (zh) 2018-03-23 2019-03-22 用于男性避孕的非激素组合物和方法

Country Status (19)

Country Link
US (3) US10912762B2 (https=)
EP (2) EP3750538B1 (https=)
JP (1) JP7270901B2 (https=)
KR (1) KR102496504B1 (https=)
CN (1) CN112074269A (https=)
AU (1) AU2019237228B2 (https=)
BR (1) BR112020018925A2 (https=)
CA (1) CA3094016C (https=)
DK (2) DK3562485T3 (https=)
ES (2) ES2989170T3 (https=)
FI (1) FI3750538T3 (https=)
IL (1) IL277372B2 (https=)
MA (1) MA53626B1 (https=)
MX (1) MX2020009937A (https=)
PL (2) PL3562485T3 (https=)
PT (1) PT3562485T (https=)
SG (1) SG11202008794TA (https=)
UA (1) UA128502C2 (https=)
WO (1) WO2019180217A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3750538B1 (en) * 2018-03-23 2024-08-14 Pharmajor International Non-hormonal methods for male contraception comprising (r)-silodosin
IL319287A (en) 2022-11-23 2025-04-01 Pharmajor Incorporated Silodosin formulations with different release and their use in male contraceptive methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1867323A (zh) * 2003-11-10 2006-11-22 埃法尔姆公司 具有聚合物网络的低剂量片剂
CN101316934A (zh) * 2005-09-29 2008-12-03 拜耳医药保健股份公司 用于治疗泌尿系统疾病的pde抑制剂及其组合
CN102283816A (zh) * 2011-08-05 2011-12-21 北京海步国际医药科技发展有限公司 西洛多辛缓释片剂及其制备方法
US20120184591A1 (en) * 2011-01-13 2012-07-19 Watson Pharmaceuticals, Inc. Methods for treating prostatitis
CN106466333A (zh) * 2015-08-18 2017-03-01 国鼎生物科技股份有限公司 良性前列腺增生添加治疗

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1091276A (en) 1911-12-09 1914-03-24 Basf Ag Producing unsaturated terpene hydrocarbons.
US4210644A (en) 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
DE4308406C1 (de) 1993-03-12 1994-06-16 Jenapharm Gmbh Kombinationspräparat zur Kontrazeption
ATE474580T1 (de) 2000-02-15 2010-08-15 Bayer Schering Pharma Ag Zusammensetzung zur männlichen kontrazeption, norethisteron enthaltend
JP2009509984A (ja) * 2005-09-29 2009-03-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 泌尿器系障害の処置用のｐｄｅ阻害剤およびそれらの組合せ
US20100098735A1 (en) * 2006-10-05 2010-04-22 Rajesh Jain Injectable depot compositions and its process of preparation
GB0700893D0 (en) 2007-01-17 2007-02-21 King S College London Male contraceptive
MX2009009230A (es) 2007-02-28 2009-11-26 Kissei Pharmaceutical Uso de silodosina en una administracion diaria para tratar hiperplasia prostatica benigna.
WO2014118606A2 (en) * 2013-01-29 2014-08-07 Alembic Pharmaceuticals Limited A novel process for the preparation of silodosin
WO2016051782A1 (ja) 2014-09-30 2016-04-07 キッセイ薬品工業株式会社 苦味を有する薬剤の苦味をマスキングした経口投与製剤
EP3750538B1 (en) * 2018-03-23 2024-08-14 Pharmajor International Non-hormonal methods for male contraception comprising (r)-silodosin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1867323A (zh) * 2003-11-10 2006-11-22 埃法尔姆公司 具有聚合物网络的低剂量片剂
CN101316934A (zh) * 2005-09-29 2008-12-03 拜耳医药保健股份公司 用于治疗泌尿系统疾病的pde抑制剂及其组合
US20120184591A1 (en) * 2011-01-13 2012-07-19 Watson Pharmaceuticals, Inc. Methods for treating prostatitis
CN102283816A (zh) * 2011-08-05 2011-12-21 北京海步国际医药科技发展有限公司 西洛多辛缓释片剂及其制备方法
CN106466333A (zh) * 2015-08-18 2017-03-01 国鼎生物科技股份有限公司 良性前列腺增生添加治疗

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GAJANAN BHAT等: "BKP 02： prospective double blind randomised study to evaluate the efficacy of siliodosin 8 mg as on demand, reversible, male oral contraceptive", 《INDIAN JOURNAL OF UROLOGY》 *
JIN WANG等: "assessment of tamsulosin as a potential male contraceptive in healthy volunteers", 《UROLOGY》 *
KOBAYASHI K.等: "orgasm is preserved regardless of ejaculatory dysfuntion with selective alpha-1A-blocker administration", 《EUR. UROL. SUPPL.》 *
NIELS KJARGAARD等: "prazosin, an adrenergic blocking agent inadequate as male contraceptive pill", 《CONTRACEPTION》 *
YONG CHEN等: "blockade of α1A-adrenoceptor: A novel possible strategy for male contraception", 《MEDICAL HYPOTHESES》 *

Also Published As

Publication number Publication date
AU2019237228B2 (en) 2023-06-08
US10912762B2 (en) 2021-02-09
US11583518B2 (en) 2023-02-21
US20210113526A1 (en) 2021-04-22
NZ767741A (en) 2024-11-29
MX2020009937A (es) 2022-09-30
US11951095B2 (en) 2024-04-09
EP3562485A1 (en) 2019-11-06
RU2020134408A3 (https=) 2022-04-29
ES2989170T3 (es) 2024-11-25
JP7270901B2 (ja) 2023-05-11
US20230145374A1 (en) 2023-05-11
IL277372B1 (en) 2023-05-01
EP3562485B8 (en) 2020-08-19
PT3562485T (pt) 2020-08-27
BR112020018925A2 (pt) 2020-12-29
SG11202008794TA (en) 2020-10-29
RU2020134408A (ru) 2022-04-29
FI3750538T3 (fi) 2024-09-24
MA53626A (fr) 2022-03-09
EP3750538B1 (en) 2024-08-14
ES2813084T3 (es) 2021-03-22
AU2019237228A1 (en) 2020-10-01
CA3094016C (en) 2023-10-10
DK3562485T3 (da) 2020-08-24
EP3750538A1 (en) 2020-12-16
PL3750538T3 (pl) 2024-11-25
KR102496504B1 (ko) 2023-02-06
MA53626B1 (fr) 2024-09-30
WO2019180217A1 (en) 2019-09-26
UA128502C2 (uk) 2024-07-31
IL277372B2 (en) 2023-09-01
KR20200135978A (ko) 2020-12-04
CA3094016A1 (en) 2019-09-26
JP2021518438A (ja) 2021-08-02
IL277372A (en) 2020-11-30
PL3562485T3 (pl) 2020-11-16
DK3750538T3 (da) 2024-09-23
EP3562485B1 (en) 2020-07-01
US20190290615A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
US7834056B2 (en) Pharmaceutical composition for gout
WO2008015220A1 (en) Granule and orally disintegrating tablet comprising oxycodone
JP7374885B2 (ja) 子宮内膜症、子宮筋腫、多嚢胞性卵巣症候群又は腺筋症を治療するための医薬製剤
TW201919632A (zh) 治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群或子宮腺肌症之醫藥調配物
US10842759B2 (en) Pharmaceutical compositions for N-propargylamine derivative
CN106659690B (zh) 包括含有活性成分的膜包衣层的复合制剂
US11951095B2 (en) Non-hormonal compositions and methods for male contraception
CN102036669B (zh) 用于治疗早泄的药物组合物
PL194702B1 (pl) Powlekana kompozycja farmaceutyczna w stałej postaci dawkowania i lek zawierający tę kompozycję
RU2799756C2 (ru) Применение композиции для негормональной контрацепции и упаковка
HK40041318B (en) Non-hormonal methods for male contraception comprising (r)-silodosin
HK40041318A (en) Non-hormonal methods for male contraception comprising (r)-silodosin
OA21941A (en) Non-hormonal compositions and methods for male contraception.
US8426392B2 (en) Method for providing emergency contraception
JPWO2003075919A1 (ja) 塩酸ピルジカイニド含有錠剤（乾式）
US20240180871A1 (en) Modified-release silodosin compositions and use thereof in methods for male contraception
US20260053816A1 (en) Misoprostol formulation for buccal administration
WO2017100324A1 (en) Combination therapy for treating female hypoactive sexual desire disorders
WO2026043794A1 (en) Misoprostol formulation for non-oral administration

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Paris France

Applicant after: Metso pharmaceutical

Address before: Paris France

Applicant before: Metso Lab

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20201211

RJ01 Rejection of invention patent application after publication